Aquinox Pharmaceuticals Inc. (AQXP) Stock Price Down 3.4%
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price traded down 3.4% during mid-day trading on Wednesday . The stock traded as low as $7.06 and last traded at $7.11, with a volume of 106,763 shares changing hands. The stock had previously closed at $7.36.
Several equities analysts have recently issued reports on the company. Jefferies Group reiterated a “hold” rating and issued a $9.00 price target (down previously from $19.00) on shares of Aquinox Pharmaceuticals in a research note on Tuesday, March 15th. Needham & Company LLC assumed coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Leerink Swann decreased their price target on Aquinox Pharmaceuticals from $26.00 to $21.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Aquinox Pharmaceuticals presently has an average rating of “Buy” and an average price target of $19.86.
The stock’s 50-day moving average price is $7.17 and its 200 day moving average price is $9.00. The company’s market cap is $122.20 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Equities analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($1.79) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Aquinox Pharmaceuticals stock. Numeric Investors LLC bought a new position in shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 185,810 shares of the company’s stock, valued at approximately $2,319,000. Numeric Investors LLC owned 1.08% of Aquinox Pharmaceuticals as of its most recent filing with the SEC.
Aquinox Pharmaceuticals, Inc, formerly Aquinox Pharmaceuticals (USA) Inc, is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc is a wholly owned subsidiary of the Company.